Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Haifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, Giuseppe A Palumbo, Bruno Martino, Francesca Palandri, Anna Marina Liberati, Philipp le Coutre, Carmen García-Hernández, Andrey Zaritskey, Renato Tavares, Vikas Gupta, Pia Raanani, Pilar Giraldo, Mathias Hänel, Daniela Damiani, Tomasz Sacha, Catherine Bouard, Carole Paley, Ranjan Tiwari, Francesco Mannelli, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, Giuseppe A Palumbo, Bruno Martino, Francesca Palandri, Anna Marina Liberati, Philipp le Coutre, Carmen García-Hernández, Andrey Zaritskey, Renato Tavares, Vikas Gupta, Pia Raanani, Pilar Giraldo, Mathias Hänel, Daniela Damiani, Tomasz Sacha, Catherine Bouard, Carole Paley, Ranjan Tiwari, Francesco Mannelli, Alessandro M Vannucchi

Abstract

Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (N = 2233), phase 3b, expanded-access study in MF in countries without access to ruxolitinib outside a clinical trial, which included patients with low platelet counts (<100 × 109 /l) and patients without splenomegaly - populations that have not been extensively studied. The most common adverse events (AEs) were anaemia and thrombocytopenia, but they rarely led to discontinuation (overall, 5·4%; low-platelet cohort, 12·3%). As expected, rates of worsening thrombocytopenia were higher in the low-platelet cohort (all grades, 73·2% vs. 53·5% overall); rates of anaemia were similar (all grades, 52·9% vs. 59·5%). Non-haematologic AEs, including infections, were mainly grade 1/2. Overall, ruxolitinib led to meaningful reductions in spleen length and symptoms, including in patients with low platelet counts, and symptom improvements in patients without splenomegaly. In this trial, the largest study of ruxolitinib in patients with MF to date, the safety profile was consistent with previous reports, with no new safety concerns identified. This study confirms findings from the COMFORT studies and supports the use of ruxolitinib in patients with platelet counts of 50-100 × 109 /l. (ClinicalTrials.gov identifier NCT01493414).

Keywords: myelofibrosis; ruxolitinib; safety; splenomegaly; symptoms.

© 2020 British Society for Haematology and John Wiley & Sons Ltd.

References

    1. Al-Ali, H.K., Griesshammer, M., le Coutre, P., Waller, C.F., Liberati, A.M., Schafhausen, P., Tavares, R., Giraldo, P., Foltz, L., Raanani, P., Gupta, V., Tannir, B., Ronco, J.P., Ghosh, J., Martino, B. & Vannucchi, A.M. (2016) Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica, 101, 1065-1073.
    1. Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A., Tefferi, A. & International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K., 22, 437-438.
    1. Carter, G.C., Liepa, A.M., Zimmermann, A.H. & Morschhauser, F. (2008) Validation of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) in patients with relapsed/refractory mantle cell lymphoma. Blood, 112, Abstract 2376.
    1. Cella, D., Eton, D.T., Lai, J.S., Peterman, A.H. & Merkel, D.E. (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24, 547-561.
    1. Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895-2901.
    1. Cervantes, F., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R.S., Passamonti, F., Barbui, T., Barosi, G., Harrison, C.N., Knoops, L., Gisslinger, H. & COMFORT-II investigators (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 122, 4047-4053.
    1. Emanuel, R.M., Dueck, A.C., Geyer, H.L., Kiladjian, J.J., Slot, S., Zweegman, S., te Boekhorst, P.A., Commandeur, S., Schouten, H.C., Sackmann, F., Kerguelen Fuentes, A., Hernandez-Maraver, D., Pahl, H.L., Griesshammer, M., Stegelmann, F., Doehner, K., Lehmann, T., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J.C., Ranta, D., Roy, L., Cahn, J.Y., Harrison, C.N., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P.L., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., Andreasson, B., Ferarri, M.L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A. & Mesa, R.A. (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 4098-4103.
    1. Geyer, H.L., Scherber, R.M., Dueck, A.C., Kiladjian, J.J., Xiao, Z., Slot, S., Zweegman, S., Sackmann, F., Fuentes, A.K., Hernandez-Maraver, D., Dohner, K., Harrison, C.N., Radia, D., Muxi, P., Besses, C., Cervantes, F., Johansson, P.L., Andreasson, B., Rambaldi, A., Barbui, T., Vannucchi, A.M., Passamonti, F., Samuelsson, J., Birgegard, G. & Mesa, R.A. (2014) Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 123, 3803-3810.
    1. Gupta, V., Griesshammer, M., Martino, B., Foltz, L., Tavares, R., Al-Ali, H.K., Giraldo, P., Guglielmelli, P., Lomaia, E., Bouard, C., Perez Ronco, J., Tiwari, R. & Raanani, P. (2017) Predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study, PF616.
    1. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366, 787-798.
    1. Harrison, C.N., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Knoops, L., Cervantes, F., Jones, M.M., Sun, K., McQuitty, M., Stalbovskaya, V., Gopalakrishna, P. & Barbui, T. (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia, 30, 1701-1707.
    1. Harrison, C.N., Koschmieder, S., Foltz, L., Guglielmelli, P., Flindt, T., Koehler, M., Mathias, J., Komatsu, N., Boothroyd, R.N., Spierer, A., Perez Ronco, J., Taylor-Stokes, G., Waller, J. & Mesa, R.A. (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: Results from the international MPN landmark survey. Annals of Hematology, 96, 1653-1665.
    1. Iurlo, A. & Cattaneo, D. (2017) Treatment of myelofibrosis: old and new strategies. Clinical Medicine Insights Blood Disorders, 10, 1179545X17695233.
    1. Jakafi (ruxolitinib)(2017) package insert. Incyte Corporation, Wilmington, Delaware, USA.
    1. Jakavi (ruxolitinib) (2016) [summary of product characteristics]. Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, UK.
    1. Landtblom, A.R., Bower, H., Andersson, T.M., Dickman, P.W., Samuelsson, J., Bjorkholm, M., Kristinsson, S.Y. & Hultcrantz, M. (2018) Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia, 32, 2203-2210.
    1. Mesa, R., Miller, C.B., Thyne, M., Mangan, J., Goldberger, S., Fazal, S., Ma, X., Wilson, W., Paranagama, D.C., Dubinski, D.G., Boyle, J. & Mascarenhas, J.O. (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer, 16, 167.
    1. Palandri, F., Palumbo, G.A., Bonifacio, M., Tiribelli, M., Benevolo, G., Martino, B., Abruzzese, E., D'Adda, M., Polverelli, N., Bergamaschi, M., Tieghi, A., Cavazzini, F., Ibatici, A., Crugnola, M., Bosi, C., Latagliata, R., Di Veroli, A., Scaffidi, L., de Marchi, F., Cerqui, E., Anaclerico, B., De Matteis, G., Spinsanti, M., Sabattini, E., Catani, L., Aversa, F., Di Raimondo, F., Vitolo, U., Lemoli, R.M., Fanin, R., Merli, F., Russo, D., Cuneo, A., Bacchi Reggiani, M.L., Cavo, M., Vianelli, N. & Breccia, M. (2017) Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget, 8, 79073-79086.
    1. Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., Pascutto, C., Lazzarino, M., Cazzola, M. & Tefferi, A. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 1703-1708.
    1. Passamonti, F., Gupta, V., Martino, B., Foltz, L., Zaritksey, A., Al-Ali, H.K., Tavares, R., Maffioli, M., Raanani, P., Giraldo, P., Griesshammer, M., Bouard, C., Ronco, J.P., Tiwari, R. & Vannucchi, A.M. (2017) Comparing the safety and efficacy of ruxolitinib (RUX) in patients (PTS) with DIPSS low/intermediate-1-, intermediate-2-, and high-risk myelofibrosis (MF) in JUMP, a phase 3B, expanded-access study. Haematologica, 102, Abstract E1333.
    1. Rumi, E. & Cazzola, M. (2017) Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood, 129, 680-692.
    1. Talpaz, M., Paquette, R., Afrin, L., Hamburg, S.I., Prchal, J.T., Jamieson, K., Terebelo, H.R., Ortega, G.L., Lyons, R.M., Tiu, R.V., Winton, E.F., Natrajan, K., Odenike, O., Claxton, D., Peng, W., O'Neill, P., Erickson-Viitanen, S., Leopold, L., Sandor, V., Levy, R.S., Kantarjian, H.M. & Verstovsek, S. (2013) Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. Journal of Hematology & Oncology, 6, 81.
    1. Tefferi, A. (2014) Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 89, 915-925.
    1. Tefferi, A. (2016) Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 91, 1262-1271.
    1. Vannucchi, A.M., Kantarjian, H.M., Kiladjian, J.J., Gotlib, J., Cervantes, F., Mesa, R.A., Sarlis, N.J., Peng, W., Sandor, V., Gopalakrishna, P., Hmissi, A., Stalbovskaya, V., Gupta, V., Harrison, C. & Verstovsek, S. (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 100, 1139-1145.
    1. Vannucchi, A.M., te Boekhorst, P.A.W., Harrison, C.N., He, G., Caramella, M., Niederwieser, D., Boyer-Perrard, F., Duan, M., Francillard, N., Molloy, B., Wroclawska, M. & Gisslinger, H. (2019) EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica, 104, 947-954.
    1. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
    1. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I., Sun, W., Sandor, V. & Kantarjian, H.M. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine, 366, 799-807.
    1. Verstovsek, S., Gotlib, J., Gupta, V., Atallah, E., Mascarenhas, J., Quintas-Cardama, A., Sun, W., Sarlis, N.J., Sandor, V., Levy, R.S., Kantarjian, H.M. & Mesa, R.A. (2013) Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy, 7, 13-21.
    1. Verstovsek, S., Gotlib, J., Mesa, R.A., Vannucchi, A.M., Kiladjian, J.J., Cervantes, F., Harrison, C.N., Paquette, R., Sun, W., Naim, A., Langmuir, P., Dong, T., Gopalakrishna, P. & Gupta, V. (2017a) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology & Oncology, 10, 156.
    1. Verstovsek, S., Mesa, R.A., Gotlib, J., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M.W., Miller, C.B., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H. Jr, Arcasoy, M.O., Hexner, E.O., Lyons, R.M., Paquette, R., Raza, A., Jones, M., Kornacki, D., Sun, K., Kantarjian, H. & COMFORT-I investigators (2017b) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematology & Oncology, 10, 55.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner